title: Insulin therapy and fetoplacental vascular function in gestational diabetes mellitus.
abstract: What is the topic of this review? This review focuses on the effects of insulin therapy on fetoplacental vasculature in gestational diabetes mellitus and the potentiating effects of adenosine on this therapy. What advances does it highlight? This review highlights recent studies exploring a potential functional link between insulin receptors and their dependence on adenosine receptor activation (insulin-adenosine axis) to restore placental endothelial function in gestational diabetes mellitus. Gestational diabetes mellitus (GDM) is a disease that occurs during pregnancy and is associated with maternal and fetal hyperglycaemia. Women with GDM are treated via diet to control their glycaemia; however, a proportion of these patients do not achieve the recommended values of glycaemia and are subjected to insulin therapy until delivery. Even if a diet-treated GDM pregnancy leads to normal maternal and newborn glucose levels, fetoplacental vascular dysfunction remains evident. Thus, control of glycaemia via diet does not prevent GDM-associated fetoplacental vascular and metabolic alterations. We review the available information regarding insulin therapy in the context of its potential consequences for fetoplacental vascular function in GDM. We propose the possibility that insulin therapy to produce normoglycaemia in the mother and newborn may require additional therapeutic measures to restore the normal metabolic condition of the vascular network in GDM. A role for A1 and A2A adenosine receptors and insulin receptors A and B as well as a potential functional link in the cell signalling associated with the activation of these receptors is proposed. This possibility could be helpful for the planning of strategies, including adenosine receptor-improved insulin therapy, for the treatment of GDM patients, thereby promoting the wellbeing of the growing fetus, newborn and mother.
authors.affiliation: Cellular and Molecular Physiology Laboratory (CMPL), Division of Obstetrics and Gynaecology, School of Medicine, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile; University of Queensland Centre for Clinical Research (UQCCR), Faculty of Medicine and Biomedical Sciences, University of Queensland, Herston, Queensland, Australia; Department of Physiology, Faculty of Pharmacy, Universidad de Sevilla, Seville, Spain.
authors.forename: Luis
authors.initials: L
authors.lastname: Sobrevia
authors.forename: Rocío
authors.initials: R
authors.lastname: Salsoso
authors.forename: Tamara
authors.initials: T
authors.lastname: Sáez
authors.forename: Carlos
authors.initials: C
authors.lastname: Sanhueza
authors.forename: Fabián
authors.initials: F
authors.lastname: Pardo
authors.forename: Andrea
authors.initials: A
authors.lastname: Leiva
mesh_terms: D016640:Diabetes, Gestational / Q000188:drug therapy* / Q000503:physiopathology*; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007328:Insulin / Q000627:therapeutic use*; D021041:Placental Circulation / Q000502:physiology*; D010925:Placental Function Tests / Q000379:methods; D011247:Pregnancy
chemical_list: D007328:Insulin